In diabetic rats, GLP-1 receptor agonists (liraglutide, dulaglutide) reduced brain infarct size more effectively than the SGLT2 inhibitor canagliflozin, with liraglutide achieving the smallest infarcts and GLP-1 drugs uniquely reducing microglial neuroinflammation.
2.9% vs 6.2% infarct volumeLiraglutide vs canagliflozin brain infarct size in diabetic rats — GLP-1 drugs achieved significantly smaller strokes
What the researchers found
Liraglutide achieved the smallest brain infarcts (2.9% vs 6.2% canagliflozin, vs 17.5% untreated DM). Both GLP-1RAs reduced hippocampal microglial activation while canagliflozin did not, indicating a unique anti-neuroinflammatory mechanism for GLP-1 drugs.
Why it matters
Diabetic patients face doubled stroke risk and worse outcomes. Knowing which diabetes drugs also protect the brain helps clinicians choose treatments that address both metabolic and neurological risks. This direct comparison provides head-to-head evidence favoring GLP-1 drugs for neuroprotection.
The numbers in context
Multiple drug comparisons were made between short-acting and long-acting GLP-1RAs versus SGLT2 inhibitors in diabetic rats with and without stroke.
How the study worked
Rat study using high-fat diet + nicotinamide/streptozotocin diabetes model. 5 groups (n=15 each): untreated DM, liraglutide, dulaglutide, canagliflozin, and non-DM control. After 8 weeks, 10/group underwent middle cerebral artery occlusion for stroke modeling. Assessed infarct volume, neurological deficit, neurofilament light chains, S100BB, microglial activation (Iba-1), and neuronal survival.
Who was studied
Rats with induced type 2 diabetes, with and without stroke
What this study cannot tell us
Rat model — metabolic and neurological responses may differ from humans. Small sample sizes per group. The streptozotocin/high-fat diet model imperfectly replicates human type 2 diabetes. Drug doses may not directly translate to human equivalent doses. Short treatment duration (8 weeks).
How to read the evidence
Preliminary evidence from an animal study with head-to-head drug comparison. Provides mechanistic insights but requires human validation.
When this study was published
Published in 2024. Contributes to the rapidly growing preclinical evidence for GLP-1 drug neuroprotection.
The bigger picture
This study adds to growing evidence that GLP-1 drugs have neuroprotective properties beyond metabolic control. The finding that they uniquely modulate microglial activation — reducing brain inflammation — provides a mechanistic explanation for the neurological benefits being observed in large human cohort studies.
Questions still open
- Would semaglutide show even stronger neuroprotective effects than liraglutide in this model?
- Does the GLP-1 microglial modulation translate to reduced neuroinflammation in human stroke patients?
- Would combination GLP-1RA + SGLT2i therapy provide additive neuroprotection?
Common questions
Why might GLP-1 drugs protect the brain better than SGLT2 inhibitors?
Should diabetic patients at stroke risk choose GLP-1 drugs based on this study?
Read the original research
Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.
Frontiers in bioscience (Landmark edition), 29(7), 265
Citation
Simanenkova, Anna; Fuks, Oksana; Timkina, Natalya; Islamova, Alina; Sufieva, Dina; Kirik, Оlga; Korzhevskii, Dmitrii; Vlasov, Timur; Karonova, Tatiana. (2024). Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.. Frontiers in bioscience (Landmark edition), 29(7), 265. https://doi.org/10.31083/j.fbl2907265